Tokyo Tape
Sign in
← Chiome Bioscience

Half-year report · Q2

4583.TEDINET S100WIB0
Period2025-01-01 → 2025-06-30
Filed2025-08-12
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 42
MetricValuePeriodScopeSource row
Revenue¥252m2025-01-01 → 2025-06-30StandaloneNet sales
Revenue¥781m2024-01-01 → 2024-12-31StandaloneNet sales (5-year summary)
Revenue¥264m2024-01-01 → 2024-06-30StandaloneNet sales
Operating income−¥537m2025-01-01 → 2025-06-30StandaloneOperating income
Operating income−¥581m2024-01-01 → 2024-06-30StandaloneOperating income
Ordinary income−¥539m2025-01-01 → 2025-06-30StandaloneOrdinary income
Ordinary income−¥1.0bn2024-01-01 → 2024-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥563m2024-01-01 → 2024-06-30StandaloneOrdinary income
Profit before tax−¥539m2025-01-01 → 2025-06-30StandaloneIncome before income taxes
Profit before tax−¥562m2024-01-01 → 2024-06-30StandaloneIncome before income taxes
Net income−¥540m2025-01-01 → 2025-06-30StandaloneProfit loss
Net income−¥1.0bn2024-01-01 → 2024-12-31StandaloneNet income loss (5-year summary)
Net income−¥564m2024-01-01 → 2024-06-30StandaloneProfit loss
Total assets¥2.0bnat 2025-06-30StandaloneAssets
Total assets¥2.5bnat 2024-12-31StandaloneAssets
Total assets¥1.6bnat 2024-06-30StandaloneTotal assets (5-year summary)
Total liabilities¥443mat 2025-06-30StandaloneLiabilities
Total liabilities¥549mat 2024-12-31StandaloneLiabilities
Net assets / equity¥1.5bnat 2025-06-30StandaloneNet assets
Net assets / equity¥1.9bnat 2024-12-31StandaloneNet assets
Net assets / equity¥1.1bnat 2024-06-30StandaloneNet assets (5-year summary)
Cash and deposits¥1.5bnat 2025-06-30StandaloneCash and deposits
Cash and deposits¥2.1bnat 2024-12-31StandaloneCash and deposits
Cash & equivalents¥1.5bnat 2025-06-30StandaloneCash and cash equivalents
Cash & equivalents¥2.1bnat 2024-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.1bnat 2024-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.3bnat 2023-12-31vStandaloneCash and cash equivalents
Operating cash flow−¥673m2025-01-01 → 2025-06-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.0bn2024-01-01 → 2024-12-31StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥677m2024-01-01 → 2024-06-30StandaloneNet cash provided by used in operating activities
Financing cash flow¥85m2025-01-01 → 2025-06-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.7bn2024-01-01 → 2024-12-31StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥455m2024-01-01 → 2024-06-30StandaloneNet cash provided by used in financing activities
EPS (basic)¥-7.972025-01-01 → 2025-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-17.542024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-10.212024-01-01 → 2024-06-30StandaloneBasic earnings loss per share (5-year summary)
Equity ratio76.9%at 2025-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio77.4%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio68.0%at 2024-06-30StandaloneEquity to asset ratio (5-year summary)
Shares issued68,053,800at 2025-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued66,969,000at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued56,387,000at 2024-06-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 16
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2025-01-01 → 2025-06-30−¥280m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2025-01-01 → 2025-06-30−¥396m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue2025-01-01 → 2025-06-30¥252m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue external2025-01-01 → 2025-06-30¥252m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentsegment profit2025-01-01 → 2025-06-30¥139m
Total Of Reportable Segments And Otherssegment totalrevenue2025-01-01 → 2025-06-30¥252m
Total Of Reportable Segments And Otherssegment totalrevenue external2025-01-01 → 2025-06-30¥252m
Total Of Reportable Segments And Otherssegment totalsegment profit2025-01-01 → 2025-06-30−¥257m
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-06-30−¥269m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2024-01-01 → 2024-06-30−¥447m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue2024-01-01 → 2024-06-30¥264m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue external2024-01-01 → 2024-06-30¥264m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentsegment profit2024-01-01 → 2024-06-30¥135m
Total Of Reportable Segments And Otherssegment totalrevenue2024-01-01 → 2024-06-30¥264m
Total Of Reportable Segments And Otherssegment totalrevenue external2024-01-01 → 2024-06-30¥264m
Total Of Reportable Segments And Otherssegment totalsegment profit2024-01-01 → 2024-06-30−¥312m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 427
ItemContextValueUnit
Current liabilitiesCurrentQuarterInstant_NonConsolidatedMember388057000JPY
Asset retirement obligations nclPrior1YearInstant_NonConsolidatedMember55120000JPY
Asset retirement obligations nclCurrentQuarterInstant_NonConsolidatedMember55336000JPY
Noncurrent liabilitiesPrior1YearInstant_NonConsolidatedMember55120000JPY
Noncurrent liabilitiesCurrentQuarterInstant_NonConsolidatedMember55336000JPY
LiabilitiesPrior1YearInstant_NonConsolidatedMember548553000JPY
LiabilitiesCurrentQuarterInstant_NonConsolidatedMember443394000JPY
Capital stockPrior1YearInstant_NonConsolidatedMember995525000JPY
Capital stockCurrentQuarterInstant_NonConsolidatedMember1065558000JPY
Capital surplusPrior1YearInstant_NonConsolidatedMember1935799000JPY
Capital surplusCurrentQuarterInstant_NonConsolidatedMember2005832000JPY
Retained earningsPrior1YearInstant_NonConsolidatedMember-1020776000JPY
Retained earningsCurrentQuarterInstant_NonConsolidatedMember-1561066000JPY
Treasury stockPrior1YearInstant_NonConsolidatedMember-292000JPY
Treasury stockCurrentQuarterInstant_NonConsolidatedMember-292000JPY
Shareholders equityPrior1YearInstant_NonConsolidatedMember1910255000JPY
Shareholders equityCurrentQuarterInstant_NonConsolidatedMember1510032000JPY
Subscription rights to sharesPrior1YearInstant_NonConsolidatedMember10048000JPY
Subscription rights to sharesCurrentQuarterInstant_NonConsolidatedMember9298000JPY
Net assetsPrior1YearInstant_NonConsolidatedMember1920303000JPY
Net assetsCurrentQuarterInstant_NonConsolidatedMember1519330000JPY
Liabilities and net assetsPrior1YearInstant_NonConsolidatedMember2468857000JPY
Liabilities and net assetsCurrentQuarterInstant_NonConsolidatedMember1962725000JPY
Net salesPrior1YTDDuration_NonConsolidatedMember263728000JPY
Net salesCurrentYTDDuration_NonConsolidatedMember251796000JPY
Cost of salesPrior1YTDDuration_NonConsolidatedMember128970000JPY
Cost of salesCurrentYTDDuration_NonConsolidatedMember112930000JPY
Gross profitPrior1YTDDuration_NonConsolidatedMember134758000JPY
Gross profitCurrentYTDDuration_NonConsolidatedMember138866000JPY
Research and development expenses sgaPrior1YTDDuration_NonConsolidatedMember446817000JPY
Research and development expenses sgaCurrentYTDDuration_NonConsolidatedMember395868000JPY
Other sgaPrior1YTDDuration_NonConsolidatedMember269077000JPY
Other sgaCurrentYTDDuration_NonConsolidatedMember279819000JPY
Selling general and administrative expensesPrior1YTDDuration_NonConsolidatedMember715894000JPY
Selling general and administrative expensesCurrentYTDDuration_NonConsolidatedMember675688000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember-581136000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember-536822000JPY
Interest income noiPrior1YTDDuration_NonConsolidatedMember20000JPY
Interest income noiCurrentYTDDuration_NonConsolidatedMember910000JPY
Foreign exchange gains noiPrior1YTDDuration_NonConsolidatedMember519000JPY
Foreign exchange gains noiCurrentYTDDuration_NonConsolidatedMember220000JPY
Subsidy income noiPrior1YTDDuration_NonConsolidatedMember19738000JPY
Subsidy income noiCurrentYTDDuration_NonConsolidatedMember－JPY
Other noiPrior1YTDDuration_NonConsolidatedMember798000JPY
Other noiCurrentYTDDuration_NonConsolidatedMember132000JPY
Non operating incomePrior1YTDDuration_NonConsolidatedMember21077000JPY
Non operating incomeCurrentYTDDuration_NonConsolidatedMember1263000JPY
Interest expenses noePrior1YTDDuration_NonConsolidatedMember1282000JPY
Interest expenses noeCurrentYTDDuration_NonConsolidatedMember1940000JPY
Stock issuance cost noePrior1YTDDuration_NonConsolidatedMember2004000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identitynon_consolidated 2024-12-31pass rounding
balance sheet identitynon_consolidated 2025-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · net assetsnon_consolidated 2025-06-30pass
statement vs summary · operating cash flownon_consolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flownon_consolidated 2025-01-01/2025-06-30pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-06-30pass
statement vs summary · revenuenon_consolidated 2025-01-01/2025-06-30pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass
statement vs summary · total assetsnon_consolidated 2025-06-30pass